4basebio Plc - Notice of Investor Presentation
News provided by
4basebio Plc16 Jun, 2026, 06:00 GMT
4basebio PLC
("4basebio" or the "Company")
Notice of Investor Presentation
CAMBRIDGE, UK – 16 June 2026 – 4basebio PLC (AIM: 4BB),a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces that it will provide a live investor presentation on 29 June 2026.
Dr. Amy Walker, Chief Executive Officer, and Christine Wolosin, Chief Commercial Officer, will provide a live presentation via the Investor Meet Company platform on 29 June 2026 at 17:00 BST. No new material information will be disclosed during the event.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 28 Jun 2026, 09:00 BST, or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet 4basebio PLC via:
https://www.investormeetcompany.com/4basebio-plc/register-investor
Investors who already follow 4basebio PLC on the Investor Meet Company platform will automatically be invited.
For further enquiries, please contact:
| 4basebio PLC |
| Dr. Amy Walker, CEO |
| +44 (0)12 2396 7943 |
| Cairn Financial Advisers LLP (Nominated Adviser) |
| Jo Turner / Sandy Jamieson / Ed Downes +44 (0)20 7213 0880 |
| Cavendish Capital Markets Limited (Joint Broker) |
| Geoff Nash / Nigel Birks +44 (0)20 7220 0500 |
| RBC Capital Markets (Joint Broker) |
| Kathryn Deegan / Matthew Coakes +44 (0)20 7653 4000 |
| ICR Healthcare (Media and Investor Relations) |
| Mary-Jane Elliott / Jessica Hodgson +44 (0)203 707 5700 |
About 4basebio
4basebio (AIM: 4BB) is a Cambridge-based biotechnology company pioneering the use of synthetic DNA to enable next-generation therapeutics and vaccines. Through its proprietary enzymatic DNA synthesis platform, 4basebio produces GMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability, overcoming the limitations of plasmid-based systems. The company offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines, helping partners accelerate proof-of-concept studies and reach clinical milestones more efficiently while maintaining the highest standards of safety and quality.
For more information, visit 4basebio.com .
The content and accuracy of news releases published on this site and/or distributed by PR Newswire or its partners are the sole responsibility of the originating company or organisation. Whilst every effort is made to ensure the accuracy of our services, such releases are not actively monitored or reviewed by PR Newswire or its partners and under no circumstances shall PR Newswire or its partners be liable for any loss or damage resulting from the use of such information. All information should be checked prior to publication.
